Freeflow Ventures

Founder David Fleck and Managing Partner Kevin Barrett set investment strategy and lead deal execution. Fleck brings early-stage venture and operating experience from Google and Disqus, while Barrett previously ran Altegra Health through a $900M+ exit to Change Healthcare. The firm also draws on a Scientific Advisory Board of Caltech and Berkeley professors to evaluate the underlying science.

Freeflow focuses almost exclusively on the research ecosystems of Caltech and UC Berkeley. The firm invests significant time — averaging 10 months — building relationships with founders before making a commitment, which it considers its primary sourcing moat. It does not claim proprietary flow in a legal sense, but its concentrated campus-level presence is designed to surface opportunities before they reach broader venture markets.

Freeflow invests from pre-seed through Series B, often as the first institutional investor. The firm actively uses SPVs for breakout portfolio companies, offering co-investment to its LP base as those companies scale. Its Fund One and Fund Two target early-stage exposure, while the 2024 Opportunity Fund was raised specifically to capture follow-on allocations.

The firm splits its portfolio between human health and planetary health. Human health includes therapeutics, diagnostics, medical devices, drug discovery platforms, consumer health, and biomanufacturing. Planetary health spans carbon capture, energy storage, water treatment, geospatial data, automation, and advanced electronics. The common thread is deep tech that leverages AI, machine learning, and proprietary IP.